Daniel Molnar

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Knee Osteoarthritis

Respiratory Syncytial Virus

Top Venues

Infectious diseases and therapy

Expert review of vaccines

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Daisuke Kurai, Akiko Mizukami, Victor Preckler, Frederik Verelst, Daniel Molnar, Taizo Matsuki, Yufan Ho, Ataru Igarashi
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis. Expert review of vaccines 23 (1) (2024)
Daisuke Kurai, Akiko Mizukami, Victor Preckler, Frederik Verelst, Daniel Molnar, Taizo Matsuki, Yufan Ho, Ataru Igarashi
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis. Expert review of vaccines 23 (1) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy 13 (4) (2024)
Daniel Molnar, Elizabeth M La, Frederik Verelst, Sara Poston, Jonathan Graham, Laure-Anne Van Bellinghen, Desmond Curran
Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States. Infectious diseases and therapy (2024)
Daniel Molnar, Anastassia Anastassopoulou, Barbara Poulsen Nautrup, Ruprecht Schmidt-Ott, Martin Eichner, Markus Schwehm, Gaël Dos Santos, Bernhard Ultsch, Rafik Bekkat-Berkani, Alfred von Krempelhuber, Ilse Van Vlaenderen, Laure-Anne Van Bellinghen
Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany. Human vaccines & immunotherapeutics 18 (5) (2022)